If You Invested in LakeShore Biopharma Co (LSBCF)

LakeShore Biopharma Co., Ltd (LSBCF), previously known as YS Biopharma, is described as a global biopharmaceutical company dedicated to discovering, developing, manufacturing, and delivering new generations of vaccines and therapeutic biologics for infectious diseases and cancer. According to company disclosures, its shares trade on the OTC Pink Open Market under the symbol LSBCF following a transition from The Nasdaq Capital Market.

The company states that it has developed a proprietary PIKA® immunomodulating technology platform and a new generation of preventive and therapeutic biologics targeting rabies, hepatitis B, influenza, and other virus infections. These activities place LakeShore Biopharma in the biopharmaceutical and vaccine development space, with a focus on infectious disease and oncology-related biologics.

LakeShore Biopharma reports that it operates in China, Singapore, and the Philippines. The company highlights that it is led by a management team combining local expertise and global experience in the biopharmaceutical industry. While specific product names, revenue details, or pipeline stages are not provided in the available information, the emphasis on vaccines, therapeutic biologics, and the PIKA platform indicates a focus on immunology-driven approaches to disease prevention and treatment.

The company has also disclosed important developments regarding its trading status. It received a delisting determination letter from Nasdaq based on non-compliance with the minimum bid price requirement under Nasdaq Listing Rule 5550(a)(2) and ineligibility for a compliance period under Nasdaq Listing Rule 5810(c)(3)(A)(iv) due to a prior reverse stock split. As a result, its ordinary shares and warrants were suspended from trading on Nasdaq and began trading on the OTC Pink Open Market under the symbols LSBCF and LSBWF.

LakeShore Biopharma has further announced that it entered into an Agreement and Plan of Merger with Oceanpine Skyline Inc. and Oceanpine Merger Sub Inc. Under this agreement, Oceanpine Merger Sub Inc. will merge with and into LakeShore Biopharma, with the company continuing as the surviving entity and becoming a wholly owned subsidiary of Oceanpine Skyline Inc. The transaction is structured as a going‑private merger, implying an equity value for the company and providing cash consideration per ordinary share to shareholders other than specified excluded and dissenting shares, as described in the merger announcement.

The merger is subject to customary closing conditions, including shareholder approval. Certain existing shareholders identified as rollover shareholders have agreed to cancel their shares in exchange for newly issued shares of the parent entity and to vote their holdings in favor of the merger. If completed, the company has stated that it will become a privately held company and that its shares will no longer be quoted on the OTC Pink Open Market.

LakeShore Biopharma has indicated that it remains a reporting company with the U.S. Securities and Exchange Commission in connection with these developments and that it intends to maintain transparency with shareholders and the public through its regulatory filings and communications.

Business focus

Based on available disclosures, LakeShore Biopharma’s business focus centers on:

• Discovering and developing vaccines and therapeutic biologics for infectious diseases and cancer.
• Using its proprietary PIKA immunomodulating technology platform.
• Developing preventive and therapeutic biologics targeting rabies, hepatitis B, influenza, and other virus infections.
• Operating across China, Singapore, and the Philippines.

Trading and corporate status

The company’s ordinary shares and warrants were previously listed on The Nasdaq Capital Market under the symbol LSB. Following a Nasdaq delisting determination related to minimum bid price requirements and prior reverse stock split history, trading of the ordinary shares and warrants moved to the OTC Pink Open Market under LSBCF and LSBWF. In a subsequent step, LakeShore Biopharma entered into a definitive going‑private merger agreement that, if completed, will result in the company becoming a wholly owned subsidiary of Oceanpine Skyline Inc. and its shares ceasing to be quoted on the OTC Pink Open Market.

Geographic footprint

LakeShore Biopharma reports operations in China, Singapore, and the Philippines. These locations are presented by the company as part of its global biopharmaceutical platform and reflect its presence in multiple Asian markets.

Technology platform

The company highlights its proprietary PIKA immunomodulating technology platform as a core element of its approach to developing new generations of vaccines and therapeutic biologics. According to its description, this platform underpins products and candidates targeting rabies, hepatitis B, influenza, and other viral infections.

Corporate evolution

LakeShore Biopharma notes that it was previously known as YS Biopharma. The available information does not elaborate on the timing or rationale for the name change, but it indicates a corporate evolution from the earlier identity to the current LakeShore Biopharma brand.

Regulatory and shareholder communications

In connection with the going‑private merger, LakeShore Biopharma has stated that it will furnish a current report on Form 6‑K to the U.S. Securities and Exchange Commission including the merger agreement as an exhibit. It has also indicated that it will prepare and mail a proxy statement to shareholders and file a Schedule 13E‑3 transaction statement with the SEC, which will include the proxy statement. These documents are intended to provide shareholders with detailed information about the merger and related matters.